{"schema_version":"secwatch.filing_event.v1","accession":"0001753926-25-000966","form_type":"8-K","ticker":"VANI","cik":"0001266806","company_name":"Vivani Medical, Inc.","filed_at":"2025-06-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.801899+00:00","generated_at":"2026-05-19T04:15:53.260351+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Vivani Medical reports exenatide implant cuts liver fat 82% in obese mice","bullets":["Exenatide implant reduced liver fat by 82% vs sham in high-fat diet obese mice after 12 weeks (Oil Red O staining).","Exenatide delivered via NanoPortal technology showed durable body weight reduction in rats over 105-140 days.","Findings from corporate slide presentation furnished as Exhibit 99.1; no material financial updates.","Vivani is developing NPM-119 (exenatide implant) for metabolic indications."],"urls":{"canonical":"https://secwatch.observer/filing/0001753926-25-000966","json":"https://secwatch.observer/filing/0001753926-25-000966.json","markdown":"https://secwatch.observer/filing/0001753926-25-000966.md","text":"https://secwatch.observer/filing/0001753926-25-000966.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1266806/000175392625000966/0001753926-25-000966-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1266806/000175392625000966/vani-20250617.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T04:15:53.260351+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}